You are here

Industry News

Advamed Smart Brief

July 17, 2018
Carlsbad, Calif.-based Ra Medical Systems has filed with the Securities and Exchange Commission for an initial public offerin -More
July 17, 2018
Kypha, a St.  -More
July 17, 2018
A round of financing has brought in $22 million for Westminster, Colo.-based orthobiologics company Cerapedics.  -More
July 17, 2018
Fresenius' venture arm has made an investment worth $2 million in a round of Series B financing for Israel-based Vectorious M -More
July 17, 2018
Engineering students at the University of Texas at Austin have created a laparoscope designed like a 7-Eleven Slurpee straw t -More
July 17, 2018
A paper in the journal Nature Biomedical Engineering describes how investigators from the Canary Center at Stanford for Cance -More
July 17, 2018
The Reline MAS Midline, which is the next-generation Reline system, has been launched by NuVasive for use in spinal fusion pr -More
July 17, 2018
Supersonic Imagine has secured 510(k) clearance from the FDA for its Aixplorer Mach 30 ultrasound system, a device that enabl -More
July 17, 2018
AdvaMed has raised concerns about the FDA's product jurisdiction draft rule, saying that the proposal's definition for a comb -More
July 17, 2018
The FDA has given Stryker premarket approval for its Surpass Streamline flow diverter, a cobalt chromium braided stent, for u -More

Industry News

Stat News
If your health care is covered by Medicare, like more than 55 million of your fellow Americans, where you live partly determines what Medicare will pay for. The process for deciding what items and services are covered from region to region needs reform.
PR Newswire
SAN ANTONIO, TX., May 23, 2018 - CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company's COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse...
Helius Medical Technologies, Inc.
NEWTOWN, PA.,  April 11, 2018 - Helius Medical Technologies, Inc. (“Helius” or the “Company”) today announced the pricing of an underwritten public offering of 2,141,900 shares of its Class A common stock and warrants to purchase 2,141,900 shares of its Class A common stock at a public offering price of US$7.47 per share and accompanying warrant, before underwriting discounts and commissions.  The net proceeds to the Company from this offering, after deducting the underwriting discounts,...
PR Newswire
California-based Myoscience, Inc. announced today that it received 510k clearance from the US FDA for Smart Tip with Nerve Stim, the latest innovative tip for Myoscience’s iovera° platform technology. With the FDA clearance for Smart Tip with Nerve Stim, physicians will be able to stimulate a nerve in advance of delivering iovera° cold therapy to the treatment area, reducing patient treatment times. Additionally, the use of Smart Tip with Nerve Stim enables physicians using iovera° to access...
Media Planet
It sometimes strikes without warning. People of any age, race, ethnicity and gender are at risk. In fact, it is the leading killer of both men and women in America. It is heart disease, and each year it claims the lives of over 600,000 Americans, accounting for one-quarter of all deaths in the United States.